Cohort of Mexican Children With Diabetes Mellitus (CMC-DM)
ConditionDiabetes Mellitus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-17
SponsorHospital Regional de Alta Especialidad del Bajio
About this trial
The aim of this study is the identification of complications in diabetes mellitus pediatric patients and to compare the clinical, anthropometric, and biochemical characteristics between children in the different types of diabetes mellitus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with confirmed diagnosis of diabetes mellitus
Disqualifiers
None
Trial population
Children and adolescents (boys and girls) from 1 months to 17 years of age that had recently been diagnosed with diabetes mellitus.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 4 trial groupsGroup A: Type 1 diabetes mellitus
Group B: Type 2 diabetes mellitus
Group C: Type 1.5 diabetes mellitus
Group D: Other types of diabetes mellitus
Trial outcomes
Primary outcomes
1
Diabetic retinopathy
A microvascular complication determined by ophthalmological evaluation
Time frame
year 32
Peripheral diabetic neuropathy
A microvascular complication determined by neurological exam in either foot
Time frame
year 53
Nerve damage
A microvascular complication determined by nerve conduction study in either foot
Time frame
year 54
Microalbuminuria
A microvascular complication determined by urine albumin excretion \>= 30 mg/day
Time frame
annualSecondary outcomes
1
Body composition
Determined by body mass index (BMI) percentiles computed from physical measurements of height and weight and corresponding percentile tables
Time frame
annual2
Glycemic control
Determined by HbA1c
Time frame
annual3
Beta cell function
Determined by fasting C peptide
Time frame
annual4
Pancreatic autoimmunity
Determined by pancreas autoantibodies
Time frame
onset of diabetesSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov